21 “... to identify ongoing trials. We conducted ongoing surveillance through November 22, 2017 to identify any major...”

22 “... to identify ongoing trials. We conducted ongoing surveillance through November 22, 2017 to identify any major...”

23 “... were excluded from the analysis (2.0% vs. 0.9%, p=0.04); almost all lung cancers occurred in former...”

24 “... (pooled RR, 4.22 [95% CI, 2.21 to 8.06], N=7,339). LIMITATIONS: Tests for the direct diagnosis of LTBI...”

25

26 “... of 10% to 19%, 15% to 25%, or 5% to 20%), and measures of reclassification (e.g., number reclassified vs...”

27 “... of 10% to 19%, 15% to 25%, or 5% to 20%), and measures of reclassification (e.g., number reclassified vs...”

28

29

30

31 “... from the PLCO and ERSPC trials imply that between 20.7 percent and 50.4 percent of screen-detected...”

32 “... from the PLCO and ERSPC trials imply that between 20.7 percent and 50.4 percent of screen-detected...”

33 “..., 1.11 to 1.33]; k=22; n=8,246) and at 3 to less than 6 months (RR, 1.20 [95% CI, 1.05 to 1.38]; k=18; n...”

34 “..., 1.11 to 1.33]; k=22; n=8,246) and at 3 to less than 6 months (RR, 1.20 [95% CI, 1.05 to 1.38]; k=18; n...”

35

36